The first patient was enrolled this month in a Nanostics-sponsored clinical utility study in Calgary to quantify the impact of incorporating ClarityDX Prostate into the standard of care for the ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

Artificial intelligence can help urologists and oncologists make treatment recommendations that are objective and evidence-based.